Genomictree Inc. (228760) - Total Assets
Based on the latest financial reports, Genomictree Inc. (228760) holds total assets worth ₩120.76 Billion KRW (≈ $81.84 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genomictree Inc. - Total Assets Trend (2020–2025)
This chart illustrates how Genomictree Inc.'s total assets have evolved over time, based on quarterly financial data. Also see Genomictree Inc. stock valuation for the company's overall valuation and market capitalisation.
Genomictree Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Genomictree Inc.'s total assets of ₩120.76 Billion consist of 65.3% current assets and 34.7% non-current assets. Review total liabilities of Genomictree Inc. to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 13.5% |
| Accounts Receivable | ₩384.04 Million | 0.3% |
| Inventory | ₩265.30 Million | 0.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩1.24 Billion | 1.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Genomictree Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Genomictree Inc. stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genomictree Inc.'s current assets represent 65.3% of total assets in 2025, a decrease from 89.3% in 2020.
- Cash Position: Cash and equivalents constituted 13.5% of total assets in 2025, down from 48.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 1.0% of total assets.
Genomictree Inc. Competitors by Total Assets
Key competitors of Genomictree Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Genomictree Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.75 | 20.56 | 25.75 |
| Quick Ratio | 17.69 | 20.49 | 25.45 |
| Cash Ratio | 0.00 | 5.55 | 0.00 |
| Working Capital | ₩74.46 Billion | ₩92.91 Billion | ₩101.21 Billion |
Genomictree Inc. - Advanced Valuation Insights
This section examines the relationship between Genomictree Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.27 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -7.6% |
| Total Assets | ₩120.76 Billion |
| Market Capitalization | $194.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genomictree Inc.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Genomictree Inc.'s assets decreased by 7.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genomictree Inc. (2020–2025)
The table below shows the annual total assets of Genomictree Inc. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩120.76 Billion ≈ $81.84 Million |
-7.59% |
| 2024-12-31 | ₩130.68 Billion ≈ $88.56 Million |
-1.63% |
| 2023-12-31 | ₩132.84 Billion ≈ $90.03 Million |
-18.46% |
| 2022-12-31 | ₩162.91 Billion ≈ $110.40 Million |
-8.04% |
| 2021-12-31 | ₩177.15 Billion ≈ $120.05 Million |
+50.26% |
| 2020-12-31 | ₩117.90 Billion ≈ $79.90 Million |
-- |
About Genomictree Inc.
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect … Read more